CA
NZ
UK
AU
IND
US
…
U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol and kit which is preparing for clinical trials for the treatment of chronic ischemic cardiomyopathy. It also offers regenerative medicine solutions to veterinarians; and training programs for physicians to perform bone marrow derived stem cell protocols. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in November 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on US Stem Cell Inc (USRM.US), an OTC Pink–listed company, is limited; the company states it operates in regenerative medicine focusing on stem cell technologies and related products and services. Long-term growth may depend on scientific progress in regenerative therapies, successful product development or licensing, and wider clinical adoption, which could support revenue expansion and market interest.
Key risks include limited public disclosure and liquidity, regulatory and clinical development uncertainty, potential need for external financing, and competitive pressures in the regenerative medicine sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -2.86M | -3.84M | -2.89M | -3.84M | -2.16M |
| Net income | -3.31M | -5.04M | -2.89M | -3.84M | -2.16M |
| Selling general administrative | 1.78M | 2.28M | 2.61M | 4.45M | 5.68M |
| Gross profit | 0.06M | 1.74M | 0.21M | 1.74M | 4.59M |
| Reconciled depreciation | - | - | 0.00M | 0.24M | 0.21M |
| Ebit | -1.72M | -3.42M | -2.40M | -2.72M | -0.85M |
| Ebitda | -1.72M | -2.96M | -2.40M | -2.61M | -0.64M |
| Depreciation and amortization | 0.00M | 0.46M | - | - | 0.21M |
| Non operating income net other | - | - | - | - | 0.38M |
| Operating income | -1.72M | -3.42M | -2.40M | -3.42M | -1.10M |
| Other operating expenses | 1.80M | 6.49M | - | - | 7.80M |
| Interest expense | 0.69M | 0.98M | 0.49M | 0.98M | 1.44M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.69M | -1.00M | -0.49M | -0.98M | -1.44M |
| Income tax expense | 0.45M | 1.20M | - | - | 1.06M |
| Total revenue | 0.08M | 3.07M | 0.28M | 3.07M | 6.70M |
| Total operating expenses | 1.78M | 5.15M | 2.68M | 6.49M | 5.69M |
| Cost of revenue | 0.02M | 1.34M | 0.06M | 1.34M | 2.11M |
| Total other income expense net | -1.14M | -0.42M | -0.00M | 0.56M | 0.38M |
| Net income from continuing ops | -2.86M | -3.29M | -2.89M | -3.84M | -2.16M |
| Net income applicable to common shares | -2.86M | -3.29M | -2.89M | -3.84M | -2.16M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 0.07M | 0.09M | 0.09M | 0.09M | 1.82M |
| Other current assets | 0.06M | 0.01M | - | - | 0.04M |
| Total liab | 14.81M | 9.57M | 11.67M | 9.57M | 8.70M |
| Total stockholder equity | -14.75M | -9.48M | -11.58M | -9.48M | -6.88M |
| Deferred long term liab | - | - | - | - | 0.09M |
| Other current liab | 4.19M | 2.09M | 0.47M | 0.51M | 1.86M |
| Common stock | 0.63M | 0.42M | 0.44M | 0.42M | 0.38M |
| Capital stock | 0.63M | 0.50M | 0.44M | 0.42M | 0.38M |
| Retained earnings | -142.52M | -133.62M | -136.51M | -133.62M | -129.79M |
| Other liab | 0.05M | 0.06M | 0.06M | 0.06M | 0.19M |
| Other assets | - | - | - | - | 0.01M |
| Cash | 0.01M | 0.02M | 0.02M | - | 1.36M |
| Total current liabilities | 14.08M | 8.75M | 10.85M | 8.75M | 5.92M |
| Current deferred revenue | 0.00M | 0.05M | - | - | 0.42M |
| Net debt | 8.94M | 6.18M | 7.47M | 6.18M | 3.69M |
| Short term debt | 8.26M | 5.42M | - | - | 2.46M |
| Short long term debt | 8.26M | 7.29M | 6.72M | 5.42M | 2.46M |
| Short long term debt total | 8.95M | 6.18M | - | - | 5.05M |
| Other stockholder equity | 127.14M | 123.73M | - | - | 122.53M |
| Property plant equipment | - | - | - | - | 0.24M |
| Total current assets | 0.07M | 0.07M | 0.09M | 0.07M | 1.51M |
| Long term investments | - | - | - | 0.02M | 0.06M |
| Net tangible assets | -14.75M | -12.77M | -11.58M | -9.48M | -6.88M |
| Net receivables | 0.00M | 0.05M | 0.05M | 0.05M | 0.02M |
| Long term debt | 0.68M | 0.72M | 0.76M | 0.76M | 2.60M |
| Inventory | 0.00M | 0.01M | 0.01M | 0.01M | 0.09M |
| Accounts payable | 1.62M | 1.19M | 1.28M | 1.19M | 1.18M |
| Common stock total equity | - | - | - | - | 0.38M |
| Retained earnings total equity | - | - | - | - | -129.79M |
| Non currrent assets other | - | - | - | - | 0.01M |
| Non current assets total | 0.00M | 0.02M | 0.00M | 0.02M | 0.31M |
| Long term debt total | - | - | - | - | 2.60M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | - | 0.00M | 0.17M | 0.31M |
| Change to liabilities | 0.27M | 0.07M | 0.13M | 0.07M | 0.73M |
| Total cashflows from investing activities | - | - | - | 0.17M | 0.31M |
| Net borrowings | 0.19M | 0.80M | 0.50M | -0.36M | -1.01M |
| Total cash from financing activities | 0.27M | -0.31M | 0.50M | -0.31M | -0.54M |
| Change to operating activities | 0.02M | -0.01M | 0.02M | 0.02M | 0.19M |
| Net income | -2.86M | -3.84M | -2.89M | -3.84M | -2.16M |
| Change in cash | -0.03M | -1.36M | 0.02M | -1.36M | 0.37M |
| Begin period cash flow | 0.04M | 1.36M | 0.00M | 1.36M | 0.99M |
| End period cash flow | 0.01M | 0.02M | 0.02M | 0.00M | 1.36M |
| Total cash from operating activities | -0.30M | -1.21M | -0.48M | -1.21M | 0.60M |
| Issuance of capital stock | 0.09M | 0.28M | 0.00M | 0.05M | 0.37M |
| Depreciation | 0.69M | 0.24M | 0.00M | 0.24M | 0.21M |
| Change to inventory | -0.00M | 0.09M | 0.00M | 0.09M | -0.02M |
| Change to account receivables | -0.00M | -0.08M | -0.01M | -0.08M | -0.04M |
| Sale purchase of stock | - | - | - | - | 0.37M |
| Other cashflows from financing activities | 0.21M | 0.47M | - | - | 0.45M |
| Change to netincome | 2.27M | 2.20M | 2.27M | 2.09M | 0.92M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change receivables | - | - | - | - | -0.04M |
| Cash flows other operating | - | - | - | - | 0.77M |
| Cash and cash equivalents changes | - | - | - | - | 0.37M |
| Change in working capital | 0.29M | 0.10M | 0.14M | 0.10M | 0.64M |
| Stock based compensation | 0.38M | 0.82M | 0.70M | 0.82M | 1.23M |
| Other non cash items | 1.20M | 1.88M | 1.57M | 1.88M | 1.01M |
| Free cash flow | -0.30M | -1.21M | -0.48M | -1.21M | 0.60M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| USRM US Stem Cell Inc |
- -% |
0.00 | - | - | 0.78 | - | 109.76 | -6.33 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol and kit which is preparing for clinical trials for the treatment of chronic ischemic cardiomyopathy. It also offers regenerative medicine solutions to veterinarians; and training programs for physicians to perform bone marrow derived stem cell protocols. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in November 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
1560 Sawgrass Corporate Parkway, Sunrise, FL, United States, 33323
954 835 1500
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Tomas | CEO, Pres, CFO & Director | 1966 |
| Dr. Colleen Robb | Sr. Compliance Officer | NA |
| Mr. Phil Posa | Sr. VP of U.S. & International Sales | NA |
| Ms. Evelyn Flores | Corp. Controller | NA |
| Dr. Sergio Pinski | Medical Director & Member of Scientific Advisory Board | NA |
| Mr. James L. Greene | Clinical Operations Consultant | NA |
| Fabianne Gershon | Consultant | NA |
| Mr. Michael Tomas | CEO, President, CFO & Director | 1966 |
| Ms. Evelyn Flores | Corporate Controller | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
| No data available |
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+38.58%
Please wait processing your request...